| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 102,25 | 102,45 | 15.04. | |
| 101,60 | 103,10 | 15.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 103,10 | 80 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/zoe.htm [/URL] | ||||
| 80 | 101,60 | |||
| 10 | 100,00 | |||
| 52 | 99,50 | |||
| 16 | 51,00 | |||
| 1.002 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.160 | 0,069 | 80 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 16:01:25 | 102,80 | 110 |
| 15:38:11 | 103,20 | 45 |
| 11:09:34 | 103,55 | 17 |
| 11:09:29 | 103,25 | 20 |
| 11:09:29 | 103,20 | 80 |
| 10:42:22 | 102,80 | 100 |
| 10:30:51 | 102,80 | 1 |
| 09:04:50 | 103,50 | 35 |
| Tagesumsatz Xetra | -0,20 -0,19 % | 727 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Zoetis auf dem KeyBanc Forum: Strategisches Wachstum trotz Herausforderungen | 41 | Investing.com Deutsch | ||
| 10.03. | Zoetis auf Barclays-Konferenz: Wachstumskurs trotz Herausforderungen | 69 | Investing.com Deutsch | ||
| 10.03. | Leerink Partners reiterates Zoetis stock rating at Market Perform | 28 | Investing.com | ||
| 03.03. | Zoetis to acquire animal genomics business from Neogen: The acquisition is expected to be completed in the second half of ... | 37 | Pet Food Processing | ||
| ZOETIS Aktie jetzt für 0€ handeln | |||||
| 03.03. | Zoetis: $160 Million Acquisition Of Animal Genomics Business To Advance Precision Animal Health | 21 | pulse2.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| Mi | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| Mi | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| Mi | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| Mi | Boehringer Ingelheim Limited: Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | GlobeNewswire (Europe) | Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase... ► Artikel lesen |